The Oklahoma Health Care Authority launched an initiative to cure SoonerCare members who have been diagnosed with the hepatitis C virus (HCV). Mavyret (glecaprevir/ pibrentasvir) is now the preferred direct-acting antiviral (DAA) medication for HCV and is available without prior authorization (PA) for SoonerCare members. Removing the prior authorization allows for easier access to this medication to cure members with HCV.